Goldfinch Bio, a Cambridge, Mass., biotech startup seeking to develop precision medicines for people with kidney disease, will receive at least $109 million in a business deal with the California biopharma giant Gilead Sciences (GILD).
It’s the first major business deal cut by Goldfinch since the privately held company was created in 2016 by the Boston venture capital firm Third Rock Ventures.
